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Abstract
Cutaneous angiosarcomas of the head and neck are aggressive cancers with a mean overall survival of 30 months. We add
to the literature a case report of a 65-year-old man with a large, >10cm, unresectable, angiosarcoma of the scalp who was
treated with two cycles of liposomal doxorubicin (Caelyx) followed by electron beam radiation therapy (30Gy in
10 fractions over 2 weeks) who has sustained a complete response with a 4-year follow-up. The dose and fractionation of
the radiation therapy in this case was palliative and was not expected to give lasting local control of this lesion. It is therefore
possible that either the genetic profile of the tumour conferred radiosensitivity or that the radiation therapy induced a recall
phenomenon of the liposomal doxorubicin.
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Introduction
Angiosarcoma of the head and neck is an uncommon
aggressive cancer of the skin and soft tissues [1]. They
occur most commonly in the sixth to seventh decade
in males and may be related to previous radiation
exposure or chronic lymphedema [2], but are often
spontaneous. The size of the tumour has been found
to be a prognostic indicator [3], with patients having
lesions <10cm surviving longer than patients with
tumours >10cm. The optimal treatment for angio-
sarcomas of the skin involves complete surgical
resection, followed by local radiation therapy [4–6].
If the tumour is too extensive to consider surgical
resection, there is no standard treatment. Palliative
chemotherapy alone results in a mean survival of 7.5
months[7]and palliative radiation therapyresultsina
mean survival of 13.5–15 months [8].
There has been a report of regression of angio-
sarcomas of the skin with the use of liposomal
doxorubicin [9]. We report a case of a 65-year-old
man with a large unresectable angiosarcoma on the
scalp who was treated with two courses of liposomal
doxorubicin (Caelyx) prior to receiving electron
beam radiation therapy (3000cGy/10 fractions) and
who has had a sustained remission.
Case report
A 65-year-old male presented with a 1-year history of
a progressive bruise-like lesion with associated punc-
tate infarcts on the forehead above the glabella. The
initial biopsies showed evidence of lymphedema
thought to be secondary to complications from his
previously diagnosed temporal arteritis. Further
biopsies showed infiltrating atypical vascularchannels
with evidence of hemorrhage and were positive for
CD31 and CD34 immunohistochemistry stains. A
diagnosis of cutaneous angiosarcoma was made and
this was reviewed and confirmed by our sarcoma
pathologist.
A bone scan was obtained, as were CT scans of
the head/neck, thorax and abdomen. There were no
distant metastases nor evidence of skull involvement.
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DOI: 10.1080/13577140500043948The lesion on the forehead was a 1512cm plaque
with several satellite red papules (Figure 1).
His past medical history included temporal
arteritis/polymyalgia rheumatica, and abdominal
aortic aneurysm as well as a high-risk prostate
adenocarcinoma for which he was on leuprolide
injections.
Treatment
The lesion was considered too extensive for surgical
resection.Basedonaprevious reportitwasdecided to
start the patient on Caelyx 20mg/m
2(50mg)every 4
weeks [9]. Three weeks after the first cycle the lesion
was noted to be flatter. It was then decided to increase
the dose to 40mg/m
2 (100mg), a dose commonly
used in the metastatic breast cancer setting. Unfortu-
nately, following this second course, he developed
severe mucositis and palmar plantar erythrodysesthe-
sia, a known, dose-related, complication of liposomal
doxorubicin [10]. As well, he was noted at this time to
have progression of his lesion with periorbital edema
and further skin involvement down the nasal bridge
(Figure 2). It was elected to proceed with radiation
therapy with palliative intent. The patient was treated
supine in a perspex shell for immobilisation. Bolus
(0.5cm) was applied over the shell. An irregular
electron cut-out was used to define the treatment
area. A single superior/anterior oblique field of 9MeV
electrons was used to deliver the prescribed dose of
3000cGy to the 90% isodose curve in 10 fractions
(3 Gy/fraction) over 2 weeks.
Follow-up
As early as the first week following the completion of
the radiation therapy there was evidence of tumour
flattening and formation of eschars. At one month
follow-up it was noted that there was significant
fading of the tumour area and that the lesion had
flattened. Continued improvement with further
fading of the pigmented areas has occurred over the
ensuing months. The patient has now been followed
for 4 years and shows no evidence of disease
recurrence despite the palliative intention and doses
of the radiation therapy (Figure 3).
Discussion
Angiosarcomas of the skin are aggressive tumours
with high rates of recurrence and metastasis. The
mean overall survival with surgical resection is
30 months [1]. If surgical resection is not feasible
there currently is no standard treatment. Recent case
reports have shown promising results utilising lipo-
somal doxorubicin [9] as well as combined radiation
therapy with liposomal doxorubicin [11,12].
Pegylated liposomal doxorubicin (Caelyx) has
been shown to be effective in the treatment of
Kaposi’s sarcoma [13] and is being investigated for
use in metastatic breast cancer as well as T-cell
leukemia and gynecological malignancies [10,14].
Pegylated liposomal doxorubicin has a long serum
half-life and is able to accumulate in tumour tissues.
As liposomal doxorubicin has less ‘free’ doxorubicin
in the serum compared with doxorubicin, there is
less cardiotoxicity and myelotoxicity seen [10,15].
Doxorubicin has been shown to be a radio-
sensitizer, in vitro, at higher serum concentrations
[16]. However, in vivo the response has been more
Figure 2. Progression of cutaneous angiosarcoma following two
cycles of Caelyx
.
Figure 3. Sustained complete response 46 months post treatment.
Figure 1. Cutaneous angiosarcoma of scalp: pre-treatment.
30 C. L. Holloway et al.variable and may in fact increase tumour hypoxia and
therefore decrease the response to radiation if given
immediately prior to radiation therapy [17]. In this
case a higher dose of Caelyx (100mg) was given
1 month prior to the patient receiving radiation
therapy. Although, there was evidence of tumour
progression following the Caelyx, it may have acted
by increasing the tumour radiosensitivity.
This case report demonstrates a sustained com-
plete response of cutaneous angiosarcoma after two
cycles of Caelyx followed by high dose per fraction
(30Gy /10 fractions) radiation therapy. Previous case
reports had illustrated response to liposomal doxor-
ubicin following failed radiation therapy 40–60 Gy
(2Gy/fraction) [11,12]. The dose and fractionation
of radiation therapy in this case, as it was palliative in
intent, would not be presumed to have lasting local
control of the lesion. It is possible that the genetic
profile of the tumour conferred radiosensitivity or if
the anthracycline was incorporated into the DNA of
the tumour, we may have seen a ‘chemotherapy’
recall with the subsequent radiation therapy.
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